SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementi... See more
Feb, 6, 2023
Simufilam reduced dementia-related behavior at 9 m... See more
BXRX
Baudax Bio Inc
-52.79%
$3.41 - $1.61
Feb 7th 2023 - Mar 21st 2023
Mar, 16, 2023
By utilizing a specialized database, this study is... See more
Feb, 16, 2023
$NRBO check out all of the trials they have going ... See more
PALI
Palisade Bio Inc
-19.56%
$2.25 - $1.81
Feb 7th 2023 - Mar 21st 2023
Jan, 2, 2023
They voluntarily suspended phase 3 bc they are see... See more
Dec, 16, 2022
$PALI phase 2 coming WOOOOO!! !
Mar, 15, 2023
$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”
Feb, 6, 2023
Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.
Feb, 1, 2023
The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.
Jan, 17, 2023
$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.
Jan, 6, 2023
$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.
Jan, 4, 2023
$SAVA , VERA announced positive phase 2b results meeting primary end point.
Dec, 27, 2022
My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients
Mar, 16, 2023
By utilizing a specialized database, this study is ensuring the utmost safety and efficacy of the medication.
Feb, 16, 2023
$NRBO check out all of the trials they have going on and backed by DONG A-ST this is the making of a MEGA RUNNER.
Jan, 24, 2023
Successful phase 2 which will be final approved April 2023 .
Jan, 14, 2023
3.67 cash per share and $20+ PT's. Not to mention, consistency with positive studies and data.
Jan, 13, 2023
Phase 3 results were solid.
Jan, 3, 2023
$BXRX must be good phase 2 data
Dec, 9, 2022
I can only imagine how useful it will be clinical setting, much like a Toradol Injection is used.
Dec, 8, 2022
$SNAP $META $GOOGL $PINS gonna go up $BXRX is just getting started imo huge phase 2 trial and great fundamentals
Dec, 8, 2022
$AFRM $UPST $SOFI $DLO good fintech companies $BXRX holy shiiii amazing news with starting their trials and great fundamentals